The potentials of nanotechnology-based drug delivery system for treatment of ovarian cancer

References

• Ali E, Rahimi E, Akahavan S. 2012. Cancer during pregnancy. A review of 10 years of experience. Pak J Biolog Sci. 15:341–346.
   PubMedGoogle Scholar
• Armstrong DK. 2002. Relapsed ovarian cancer: challenges and management strategies for a chronic disease. Oncol. 7:20–28.
   Google Scholar
• Bai S, Thomas C, Rawat A, Ahsan F. 2006. Recent progress in dendrimer-based nanocarriers. Crit Rev Ther Drug Carrier Syst. 23:437–495.
   PubMed Web of Science ®Google Scholar
• Bayindir ZS, Yuksel N. 2010. Characterization of niosomes prepared with various non ionic surfactants for paclitaxel oral delivery. J Pharm Sci. 99:2049–2060.
   PubMed Web of Science ®Google Scholar
• Carmo-Pereira J, Costa FO, Henriques E, Ricardo JA. 1981. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy. Cancer. 48:1947–1951.
   PubMed Web of Science ®Google Scholar
• Carsten OK, Oliver RH. 2002. Enzymatic degradation of dynasan 114 SLN – effect of surfactants and particle size. J Nanopart Res. 4: 121–129.
   Web of Science ®Google Scholar
• Chang TMS. 1964. Semi permeable Microcapsules. Science. 146: 524–525.
   PubMed Web of Science ®Google Scholar
• Chang TMS. 2007. Monograph on “Artificial Cells: Biotechnology, nanotechnology, blood substitutes, regenerative medicine, bioencapsulation, cell/stem cell therapy.” Singapore and London: World Scientific Publisher/Imperial College Press, p. 435.
   Google Scholar
• Chang TMS. 2013. Introduction chapter on “Artificial Cells that started Nanomedicine” in book on Selected Topics in Nanomedicine. Singapore and London: World Science Publisher/Imperial College Press, p. 3659.
   Google Scholar
• Chang TMS. 1976. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. J Bioeng. 1:25–32.
   PubMedGoogle Scholar
• Chauhan SC, Kumar D, Jaggi M. 2009. Mucins in ovarian cancer diagnosis and therapy. J Ovarian Res. 2:21–26.
   PubMed Web of Science ®Google Scholar
• Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, et al. 2011. A phase II evaluation of nanoparticles, albumin-bound paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 122:111–5.
   PubMed Web of Science ®Google Scholar
• Dunton CJ. 2002. Management of treatment-related toxicity in advanced ovarian cancer. Oncol. 7:11–19.
   Google Scholar
• Emami J, Rezazadeh M, Varshosaz J, Tabbakhian M, Aslani A. 2012. Formulation of LDL Targeted Nanostructured Lipid Carriers Loaded with Paclitaxel: A Detailed Study of Preparation, Freeze Drying Condition, and In Vitro Cytotoxicity. J Nanomater. 2012:1–10.
   Google Scholar
• Feng SS, Chien S. 2003. Chemotherapeutic engineering: application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci. 58: 4087–4114.
   Web of Science ®Google Scholar
• Gelderblom H, Verweij J, Nooter K. 2001. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer. 37:1590–1598.
   PubMed Web of Science ®Google Scholar
• Greco F, Vicent MJ. 2009. Combination therapy: opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines. Adv Drug Deliv Rev. 61:1203–1213.
   PubMed Web of Science ®Google Scholar
• Gref R, Domb A, Quellec P, Blunk T, Muller RH, Verbavatz JM, Langer R. 1995. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Deliv Rev. 16:215–233.
   PubMed Web of Science ®Google Scholar
• Haley B, Frenkel E. 2008. Nanoparticles for drug delivery in cancer treatment. Urol Oncol. 26:57–64.
   PubMed Web of Science ®Google Scholar
• Hoarau D, Delmas P, David S, Roux E, Leroux JC. 2004. Novel long circulating lipid nanocapsules. Pharm Res. 21:1783–1789.
   PubMed Web of Science ®Google Scholar
• Houston, TX. 2013. Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res. 19:1806–1815.
   PubMed Web of Science ®Google Scholar
• Hu, CM, Aryal S, Zhang, L. 2010Nanoparticle-assisted combination therapies for effective cancer treatment. Therapeutic Delivery. 1, 2:323–334.
   Google Scholar
• Hwang MJ, Suh JM, Bae YH, Kim SW, Jeong B. 2005. Caprolactonic poloxamer analog: PEG-PCL-PEG. Biomacromolecules. 6:885–890.
   PubMed Web of Science ®Google Scholar
• Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ. 2005. Cancer statistics. CA-Cancer J Clin. 55:10–30.
   PubMed Web of Science ®Google Scholar
• Jenning V, Lippacher A, Gohla SH. 2002. Medium scale production of solid lipid nanoparticles SLN by high-pressure homogenization. J Microencapsul. 19:1–10.
   PubMed Web of Science ®Google Scholar
• Kataoka K, Harada A, Nagasaki Y. 2001. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv Drug Deliv Rev. 47:113–7.
   PubMed Web of Science ®Google Scholar
• Kim HK, Park TG. 2002. Surface Stabilization of Diblock PEG-PLGA Micelles by Polymerization of N-Vinyl-2-pyrrolidone. Macromol Rapid Commun. 23:26–31.
   Web of Science ®Google Scholar
• Kim SC, Kim DW, Shim YH, Bang JS, Oh HS, Kim SW, Seo MH. 2001. In vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy. J Control Release. 72:191–202.
   PubMed Web of Science ®Google Scholar
• Kloover JS, Bakker MA, Gelderbolm H. 2004. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br J Canc. 90:304–305.
   PubMed Web of Science ®Google Scholar
• Lee H, Ahn CH, Park TG. 2009. Poly [lactic-co-glycolic acid]-Grafted Hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin. Macromol Biosci. 9:336–42.
   PubMed Web of Science ®Google Scholar
• Lee KE, Cho SH, Lee HB, Jeong SY, Yuk SH. 2003. Microencapsulation of lipid nanoparticles containing lipophilic drug. J Microencapsul. 20:489–496.
   PubMed Web of Science ®Google Scholar
• Li R, Eun JS, Lee MK. 2011. Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration. Arch Pharm Res. 34:331–7.
   PubMed Web of Science ®Google Scholar
• Liggins RT, Burt HM. 2002. Polyether-polyester diblock copolymers for the preparation of paclitaxel loaded polymeric micelle formulations. Adv Drug Deliv Rev. 54:191–202.
   PubMed Web of Science ®Google Scholar
• Liu J, Xiao Y, Allen C. 2004. Polymer-drug compatibility: a guide to the development of delivery systems for the anticancer agent, ellipticine. J Pharm Sci. 93:132–143.
   PubMed Web of Science ®Google Scholar
• Loftsson T, Vogensen SB, Brewster ME, Konradsdottir F. 2007. Effects of cyclodextrins on drug delivery through biological membranes. J Pharm Sci. 96:2532–2546.
   PubMed Web of Science ®Google Scholar
• Lu H, Li B, Kang Y, Jiang W, Huang Q, Chen Q, et al. 2007. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting. Cancer Chemother Pharmacol. 59:175–181.
   PubMed Web of Science ®Google Scholar
• Malzert-Freon A, Vrignaud S, Saulnier P, Lisowski V, Benot JP, Rault S. 2006.Formulation of sustained release nanoparticles loaded with a tripentone, a new anticancer agent. Int J Pharma. 320:157–164.
   Google Scholar
• Mani R, Jamil K, Vamsy MC. 2007. Specificity of serum tumor markers CA 125, CEA, AFP and Beta HCG for ovarian malignancies. Trends Med Res. 2:128–134.
   Google Scholar
• McGuire WP 3rd, Markman M. 2003. Primary ovarian cancer chemotherapy: current standards of care. Br J Canc. 89:3–8.
   PubMed Web of Science ®Google Scholar
• Meyer T, Rustin GJ. 2000. Role of tumor markers in epithelial ovarian cancer. Br J Cancer. 82:1535–1538.
   PubMed Web of Science ®Google Scholar
• Muller RH, Mader K, Gohla S. 2000. Solid lipid nanoparticles SLN for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 50:161–177.
   PubMed Web of Science ®Google Scholar
• Muller HR, Mehnert W, Lucks JJ, Schwartz C, Zur Muhlen A, Weyhers H, et al. 1995. Solid lipid nanoparticles SLN as an alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm. 41:62–68.
   Web of Science ®Google Scholar
• Ozols R. 1999. Treatment of gynecologic cancer: the US experience. Tumori, 85, S5–S11.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. 2004. Focus on epithelial ovarian cancer. Cancer Cell. 5:19–24.
   PubMed Web of Science ®Google Scholar
• Piel G, Evrard B, Van Hees T, Llabres G, Delattre L. 1999. Development of a parenteral and of an oral formulation of albendazole with cyclodextrins. STP Pharma Sci. 9:257–260.
   Google Scholar
• Purgholami MH, Wangoo KT. 2008. Albendazole-cyclodextrin complex: enhanced cytotoxicity in ovarian cancer cells. Anticancer Res. 28:2775–2780.
   PubMed Web of Science ®Google Scholar
• Siekmann B, Westesen K. 1994. Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol - I. Preparation and particle size determination. Pharmacol Lett. 3:194–197.
   Google Scholar
• Sun J, Deng Y, Wang S, Cao J, Gao X, Dong X. 2010. Liposomes incorporating sodium deoxycholate for hexamethylmelamine HMM oral delivery: development, characterization, and in vivo evaluation. Drug Deliv. 17:164–70.
   PubMed Web of Science ®Google Scholar
• Thigpen JT, Aghajanian CA, Alberts DS, Campos SM, Gordon AN, Markman M, et al. 2005. Role of pegylated liposomal doxorubicin in ovarian cancer. Gynecol Oncol. 96:10–8.
   PubMed Web of Science ®Google Scholar
• Uchegbu IF, Double JA, Kelland LR, Turton JA, Florence AT. 1996The activity of doxorubicin niosomes against an ovarian cancer cell line and three in vivo mouse tumour models. J Drug Targeting. 3: 399–409.
   PubMed Web of Science ®Google Scholar
• Vyas A, Saraf S. 2008. Cyclodextrin based novel drug delivery systems. J Incl Phenom Macrocycl Chem. 62:23–42.
   Web of Science ®Google Scholar
• Vyas A, Shukla SS, Pandey R. 2011. Development and validation of spectrophotometric method for estimation of cephalexin in bulk and tablet dosage forms. Oriental J Chemistry. 27:359–362.
   Google Scholar
• Vyas A. 2012. Preparation, characterization and pharmacodynamic activity of supramolecular and colloidal systems of rosuvastatin– cyclodextrin complexes. J Incl Phen Macrocyclic Chem. 66: 251–259.
   Google Scholar
• Yallapu M, Jaggi MM, Chauhan SC. 2010. Scope of nanotechnology in ovarian cancer therapeutics Scope of nanotechnology in ovarian cancer therapeutics. J Ovarian Res. 3:19–29.
   PubMed Web of Science ®Google Scholar
• Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. 2008Nanoparticles in medicine: therapeutic applications and developments. Clin Pharmacol Ther. 83, 5:761–769.
   PubMed Web of Science ®Google Scholar
• Zhang P, Chen L, Zhang Z, Lin L, Li Y. 2010. Pharmacokinetics in rats and efficacy in murine ovarian cancer model for solid lipid nanoparticles loading docetaxel. J Nanosci Nanotechnol. 10:7541–4.
   PubMed Web of Science ®Google Scholar
• Ziller C, Lincet H, Muller CD, Staedel C, Behr JP, Poulain L. 2004. The cyclin-dependent kinase inhibitor p21cip1/waf1 enhances the cytotoxicity of ganciclovir in HSV-tk transfected ovarian carcinoma cells. Cancer Lett. 212:43–52.
   PubMed Web of Science ®Google Scholar